

Figure 1.




Figure 2A)

a)




Figure 2 B)




Figure 2 C)




Figure 3.






Figure 4.

A)(Neat)



B) (1 ug/ml)




C) Dose dependence

Figure 5.







Figure 6.**A) Ru-labeled I3RB2****B) Ru-labeled I3RB18**

Figure 7.

A)



B)




Figure 8.

Numbering: ovals refer to residues of CD123 SP2, rectangles refer to residues of SEQ ID NO:230





Figure 9.

Figure 10.**Light Chain (SEQ ID NO:4)**

```

      10      20      30      40      50      60
      . | . | . | . | . |
QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNKRAPGV
      70      80      90      100     110     120
      . | . | . | . | . |
PARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNLWVFGGGTKLTVLGQPKSSPSVTL
      130     140     150     160     170     180
      . | . | . | . | . |
FPPSSEELTNKATLVCTITDFYPGVVTVDWKVDGTPVTQGMETTQPSKQSNNKYMASSY
      190     200     210
      . | . | . |
LTLTARAWERHSSYSCQVTHEGHTVEKSLSRADCS

```

Heavy Chain (SEQ ID NO:5)

```

      10      20      30      40      50      60
      . | . | . | . | . |
EVKLLSEGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYAT
      70      80      90      100     110     120
      . | . | . | . | . |
YYADSVKDRFTISRDDSQSILYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTL
      130     140     150     160     170     180
      . | . | . | . | . |
VTVSAATTTAPSVYPLVPGCSDTSGSSVTLGCLVKGYFPEPVTVKWNYGALSSGVRTVSS
      190     200     210     220     230     240
      . | . | . | . | . |
VLQSAFYSLSSLVTVPSSSTWPSQTVICNV AHPASKTELIKRIEPRIPKPSTPPGSSCPPG
      250     260     270     280     290     300
      . | . | . | . | . |
NILGGPSVFI FPPKPKDALMISLTPKVTCVVVDVSEDDPDVHVSWFVDNKEVHTAWTQPR
      310     320     330     340     350     360
      . | . | . | . | . |
EAQYNSTFRVVSALPIQH QDWMRGKEFKCKVNNKALPAPIERTISKPKGRAQTPQVYTIP
      370     380     390     400     410     420
      . | . | . | . | . |
PPREQMSKKKVS LTCLVTNFFSEAISVEWERNGELEQDYKNTPPILDSDGTYFLYSKLTV
      430     440     450
      . | . | . |
DTDSWLQGEIFTCSVVHEALHNHHTQKNLSRSPGK

```

Fig. 11.




Figure 12.

VH	10	20	30	40	50	60
sp34	EVKLLES	GGGLVQPKGSLKLS	CAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATY			
CD3H141	EV QLV ESGGGLVQ PGGSLRL S	CAASGFTFNTYAMNWVRQAPGKGLEW VAR IRSKYNNYATY				
CD3H142	EV QL LES	GGGLVQ PGGSLRL S	CAASGFTFNTYAMNWVRQAPGKGLEW VAR IRSKYNNYATY			
CD3H143	EV QL LES	GGGLVQ PGGSLRL S	CAASGFTFNTYAMNWVRQAPGKGLEW VAR IRSKYNNYATY			
CD3H144	EV QLV ESGGGLVQ PGGSLKLS	CAASGFTFNTYAMNWVRQ ASG KGLEW VGRI RSKY NGY ATY				
	70	80	90	100	110	120
sp34	YADSVKDRFTISRDDS	QSILYLQMN	NLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGT	TLTVSA		
CD3H141	Y AA SVK GR FTISRDDS KNS	LYLQMN SL K	TEDTAVYYC AR HGNFGNSYVSWFAYWGQGT	TLTVSS		
CD3H142	YADSVK GR FTISR DNS	KNT LYLQMN SL R	AEDTAVYYC AK HGNFGNSYVSWFAYWGQGT	TLTVSS		
CD3H143	YADSVK GR FTISR DNS	KNT LYLQMN SL R	AEDTAVYYC VK HGNFGNSYVSWFAYWGQGT	TLTVSS		
CD3H144	Y AA SVK GR FTISRDDS KNTA	YLQMN SL K	TEDTAVYYC TR HGNFGNSYVSWFAYWGQGT	TLTVSS		
VL	10	20	30	40	50	60
sp34	QAVVTQES-ALTTSPGETVTL	TCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGT	TKRAPGV			
CD3L63	QAVVTQ EP-S LT VSP GGTVTL	TCRSSTGAVTTSNYANW VQ Q KPGQAPRGLI GGT	TKRAP GT			
CD3L64	Q SV LT QPP-S V SAA PG QK VT I S	CRSSTGAVTTSNYANW VQ Q LPGTAPKGLI GGT	TKRAP GI			
CD3L66	Q T VVTQ EP-S LT VSP GGTVTL	TCRSSTGAVTTSNYANW VQ Q KPGQAPRGLI GGT	TKRAP GT			
	70	80	90	100	110	
sp34	PARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNLWVF	GGG	TKLTVL			
CD3L63	PARFSGSL LG GKAALT LS G	AQ PE DEA EY YCALWYSNLWVF	GGG	TKLTVL...		
CD3L64	PDRFSGS KSGTS AT LG IT GL Q TG DEAD Y Y	CALWYSNLWVF	GGG	TKLTVL...		
CD3L66	PARFSGSL LG GKAALT LS G	V Q PEDEA EY YCALWYSNLWVF	GGG	TKLTVL...		

Figure 13.




Figure 14.




Fig. 15.




Fig. 16.





Figure 17

A) Human



B) Cynomolgous monkey





Figure 18.

A) MV4-11, donor M6587



B) MV4-11, donor M7020





Figure 19.

A) OCI-M2, Donor M6587



B) OCI-M2, Donor M7020





Figure 20.

A) OCI-AML cell line Donor M6587



B) OCI-AML cell line Donor 7020





Figure 21.



A) CD45+






Figure 23.

A) CD45+



B) CD8+/CD4+




Figure 24.




Figure 25.





Figure 26.

A. CD45 +



B. CD8+/CD4+





Figure 27.

A) CD45 +



B) CD8+/CD4+




Figure 28.





Figure 29.

A)



B)





Figure 30.

A)



B)





Figure 31.

A)



B)





Figure 32.

A)



B)





Figure 33.

A)



B)




Figure 34.





Figure 35.






Figure 37.




Figure 38.




Figure 39.




Figure 41.




Figure 43.

